Skip to content

Add your earlier progress to your account?

From before you signed in, this browser has:

Which plan do you want to keep?

You answered the plan questions before you signed in, and those answers don't match the plan saved on your account.

SettingSaved planNew answers

Study progress is waiting to be saved

PT, APTT and mixing studies

15 min

Skills you'll build4 skills
  • Read a PT and APTT result pair to choose the next coagulation test
  • Interpret immediate and incubated mixing-study behavior
  • Match an isolated prolonged APTT to factor VIII, IX, XI, or contact-factor deficiency
  • Choose a one-stage or chromogenic factor assay and check its dilution linearity

At the bench: Review coagulation results and identify the next laboratory check

Try first

Try first

A patient's prothrombin time (PT) is normal and activated partial thromboplastin time (APTT) is markedly prolonged, with no bleeding history recorded. What does this pattern support?

Keep going to see the reasoning.

Right. Keep going to follow the reasoning.

Keep going to see the reasoning.

Keep going to see the reasoning.

Get the idea

Use the explanation to check your first decision.

Interpreting the PT and APTT

The PT depends on factor VII and the common-pathway factors X, V, II, and fibrinogen. The APTT depends on the contact factors, XI, IX, VIII, and the same common pathway.1 An isolated prolonged APTT with a normal PT can come from hemophilia, factor XI or contact-factor deficiency, a specific inhibitor, lupus anticoagulant, heparin, a direct thrombin inhibitor, or specimen contamination. The screen narrows the possibilities but does not identify the cause.1

Mixing studies

A mixing study combines patient plasma 1:1 with pooled normal plasma and repeats the prolonged assay. Normal plasma supplies about half-normal activity for a missing factor, so correction supports a deficiency. Persistent prolongation supports an inhibitor or a drug effect.2 Some inhibitors act slowly. An immediate mix can correct, and the same mix, incubated at 37 °C for about 2 hours and compared with an incubated control, can lose that correction. That pattern points to a time-dependent inhibitor, most often a factor VIII autoantibody, and factor VIII activity is the next assay.2

Factor assays

Factor XII, prekallikrein, and high-molecular-weight kininogen deficiencies can prolong the APTT markedly with intact clinical hemostasis, because the body does not start coagulation through contact activation. Factor VIII, IX, or XI deficiency prolongs the APTT and causes a bleeding tendency that follows the measured activity.3 A one-stage factor assay mixes diluted patient plasma with factor-deficient plasma and reads the correction from a calibration curve. A chromogenic assay offers a different measurement principle for factor VIII or IX and avoids interference from emicizumab, which shortens the APTT and falsely raises an APTT-based factor VIII result.4

Follow the bench demonstration

Sources for this step
References
  1. Park S, Park JK. Back to basics: the coagulation pathway. Blood Res. 2024;59(1):35. doi:10.1007/s44313-024-00040-8
  2. Clinical and Laboratory Standards Institute. One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test. 3rd ed. CLSI standard H47. Clinical and Laboratory Standards Institute; 2023. Accessed September 26, 2026. https://clsi.org/shop/standards/h47/
  3. Keohane EM, Preston MM, Mirza KM, Walenga JM, eds. Rodak's Hematology: Clinical Principles and Applications. 7th ed. Elsevier; 2025. Accessed September 26, 2026. https://www.us.elsevierhealth.com/rodaks-hematology-9780323936507.html
  4. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046

Watch one

Read each decision and its explanation.

An APTT of 82 seconds is found on a patient with a new bruising history and no medication that would explain it. Pooled normal plasma runs 28 seconds.

  1. Review the medication record. No heparin, warfarin, or direct oral anticoagulant is documented, and drug-specific testing is negative.

    A drug effect can mimic an inhibitor pattern, so it is excluded before the mixing study is interpreted.

  2. Run the immediate 1:1 mix. It corrects to 32 seconds, within the laboratory's correction criterion.

    The immediate mix shows whether normal plasma's factor activity is enough to correct the assay right away.

  3. Incubate the mix and a normal-plasma control at 37 °C for 2 hours. The incubated mix is now 57 seconds, and the incubated control stays at 29 seconds.

    Some inhibitors, especially factor VIII autoantibodies, act slowly and can be missed by the immediate mix.

  4. Interpret the pattern. Immediate correction that is lost on incubation supports a time-dependent inhibitor.

    Correction followed by loss of correction on incubation is characteristic of a time-dependent inhibitor.

Measure factor VIII activity next. A reduced result is followed by a Nijmegen-Bethesda titer to quantify the inhibitor.

Practice this skill

Your turn

Problem 1 of 3 · Hints available

A patient with no bleeding history has a markedly prolonged activated partial thromboplastin time (APTT) and a normal PT. Which deficiency fits a prolonged assay with intact clinical hemostasis?

Incorrect. Factor XI deficiency prolongs the APTT but can cause variable bleeding, especially after procedures in tissues with high fibrinolytic activity.

Correct. Factor XII, prekallikrein, and high-molecular-weight kininogen drive contact activation in the APTT assay. Hemostasis in the body proceeds normally without them, so their deficiencies can markedly prolong the assay without bleeding.

Incorrect. Factor VIII deficiency prolongs the APTT and brings a bleeding tendency that follows the measured activity, from spontaneous joint and muscle bleeding in severe disease to bleeding with surgery in mild disease.

Hint
  1. Consider which deficiencies prolong the APTT without causing bleeding.
  2. The contact factors drive the APTT reagent's own activation step, a step the body does not use to start clotting.

Review Coagulation proteins and complexes

Problem 2 of 3 · Hints available

An activated partial thromboplastin time (APTT) of 80 seconds corrects to 34 seconds on an immediate 1:1 mix, but after 2 hours at 37 °C the incubated mix is 60 seconds and the incubated control is 31 seconds. Drug testing shows no anticoagulant. What does the pattern support, and what is the next assay?

Incorrect. A simple deficiency stays corrected after incubation. Loss of correction in the incubated mix shows a time-dependent inhibitor.

Correct. Factor VIII autoantibodies and a minority of lupus anticoagulants appear only after incubation. Factor VIII activity is measured next, and a reduced result is followed by a Nijmegen-Bethesda titer.

Incorrect. A minority of lupus anticoagulants behave this way, but a mixing study only classifies the screen. A lupus anticoagulant is assigned from two phospholipid-dependent test systems.

Hint
  1. Compare the immediate mix with the incubated mix and its control.
  2. A simple factor deficiency stays corrected after incubation.

Review Mixing studies

Problem 3 of 3 · On your own

A patient on emicizumab for hemophilia A has a short APTT and an APTT-based factor VIII activity of 42 IU/dL. The treating service asks whether 42 IU/dL is the patient's own factor VIII activity. What do you report?

Emicizumab shortens the APTT and falsely raises an APTT-based factor VIII result. This number does not measure the patient's endogenous factor VIII or exclude an inhibitor.

Accepted an APTT-based factor VIII during emicizumab therapy

Emicizumab shortens the APTT and falsely raises APTT-based factor VIII activity, so the result can neither measure endogenous factor VIII nor exclude an inhibitor. A validated chromogenic factor VIII assay with bovine reagents avoids the interaction.

Emicizumab interferes with APTT-based clotting assays. A validated chromogenic factor VIII assay with bovine reagents avoids the interaction and gives a result that reflects the patient's own factor VIII.

A shortened APTT here is the expected effect of emicizumab on the reagent. The one-stage result cannot be interpreted while the drug is present.

Review Factor and inhibitor assays

Use it

Read the case evidence, then make each decision. The step is complete without it.

  • A young man (MRN 0056193) is evaluated after prolonged bleeding from a dental extraction.
  • He reports occasional joint swelling as a teenager but no other bleeding history in the family.
  • The panel below is his coagulation screen.
TestResultReference intervalFlag
PT12.8 s11.5–14.5 s11.5–14.5
APTT68 s High25–35 s25–35High

Specimen: H 2, L 5, I 1. Citrate plasma, correctly filled and centrifuged; no clot noted.

Decision 1 of 3

What does this screen pattern support?

The PT here is normal. A common-pathway deficiency, such as factor X or factor V, prolongs both the PT and the APTT.

A normal PT with a prolonged APTT narrows the cause to the factors and conditions tested only by the APTT. His joint bleeding as a teenager fits a deficiency with a bleeding phenotype, but the screen does not identify which one.

A contact-factor deficiency can prolong the APTT this much, but so can factor VIII, IX, or XI deficiency. The length of the APTT does not distinguish them.

Review Screening tests and mixing studies

Decision 2 of 3

The immediate 1:1 mix corrects to 30 seconds, and a 2-hour incubated mix stays corrected at 31 seconds against an incubated control of 29 seconds. What does this mixing pattern support?

A time-dependent inhibitor shows correction that is later lost on incubation. This mix stays corrected at both steps.

Took immediate correction as ruling out every inhibitor

Factor VIII autoantibodies act slowly, so an immediate 1:1 mix can correct and then lose correction after about 2 hours at 37 °C. Calling a deficiency from the immediate mix alone misses acquired hemophilia A, which shows up in the incubated mix read against an incubated control and then in factor VIII activity.

Correction that persists after incubation supports a missing factor. His joint bleeding history and the isolated APTT prolongation now point toward a factor VIII, IX, or XI assay.

A lupus anticoagulant would be expected to resist correction on the mix. This mix corrected and stayed corrected.

Review Mixing studies

Decision 3 of 3

Factor VIII activity returns at 3 IU/dL, and factor IX and XI activities are both normal. He is not on emicizumab or any other factor-affecting therapy. How do you classify his hemophilia?

Severity is defined by the measured activity. 3 IU/dL falls in the moderate range, above 1 and below 5 IU/dL.

3 IU/dL is above 1 IU/dL. The severe band is below 1 IU/dL.

A factor VIII activity of 3 IU/dL falls in the moderate band, 1 to 5 IU/dL, which fits bleeding after minor injury with occasional spontaneous bleeding, such as the joint swelling he reports as a teenager.

Review Screening tests and mixing studies

The normal PT with a prolonged APTT, together with his history of joint swelling, points to a factor VIII, IX, or XI deficiency. The mixing study corrected at both steps, which confirms a missing factor, and the factor assay identifies the factor and grades its severity.

For reference